People news: Teva

Share this article:
Teva named former Bristol-Myers Squibb exec Dr. Jeremy Levin to replace Shlomo Yanai, who is retiring from his role as president and CEO of the generics giant in May. Levin joined BMS in 2007 as SVP strategy, alliances and transactions, also managing the company's portfolio of alliances. Before that he served as global head of business development and strategic alliances at Novartis. Yanai, said Teva, is “moving on to a new phase in his career” after five years in the president/CEO role. On his watch, the company went from an $8.4 billion mostly generics business in 2006 to a diversified Pharma with projected 2012 revenue of $22 billion.












Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in People Moves

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters